RegulatoryOfficial

FDA launches NAIN to coordinate neurology product work across CBER, CDER and CDRH

🇺🇸 FDA CBER · Mon 26 Oct 2026

The Neuroscience Advancement and Innovation Nexus will link three FDA centres, starting with an Alzheimer's Prevention Accelerator, while review decisions stay with individual centres.

The US Food and Drug Administration has set up the Neuroscience Advancement and Innovation Nexus (NAIN), an initiative to strengthen coordination between its medical product centres and encourage innovation in products for diseases and conditions of the brain and nervous system.

NAIN draws on scientific and regulatory expertise from the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH). The page covers biologics, drugs and medical devices.

The FDA states that regulatory review and decisions on individual submissions will remain with the relevant medical product centre. NAIN is therefore presented as a coordination and expertise-sharing structure rather than a new review pathway.

Its first focus is the Alzheimer's Prevention Accelerator. This effort aims to advance the science, tools and regulatory approaches needed to support development of products intended to prevent or delay the onset or progression of cognitive decline due to Alzheimer's disease.

The source page, current as of 22 October 2026, does not set out specific mechanisms, timelines, eligibility criteria or deliverables. Any practical consequences for sponsors will depend on further information from the agency.

What it means for your team

  • Sponsors of neurology products should note that submissions will still be reviewed and decided by the appropriate centre (CBER, CDER or CDRH), not by NAIN.
  • Teams working on Alzheimer's prevention or delay of cognitive decline should watch for details of the Alzheimer's Prevention Accelerator, as none are given yet.
  • No new pharmacovigilance or quality obligations are stated; existing requirements are unchanged on the information available.
  • Developers of combination or cross-centre products may find the cross-centre coordination relevant, though the source does not describe any specific process.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.

More Regulatory All →